Revenue recognition (Tables)

9 Months Ended

Sep. 30, 2022

Revenue recognition

Schedule of disaggregated revenue

	Three Months Ended September 30, 2022								Three Months Ended September 30, 2021
	North America		EMEA		Asia Pacific		Total		North America		EMEA		Asia Pacific		Total
Product revenues
Instruments	$	2,964		3,115		1,684	$	7,763	$	3,492	$	1,644	$	1,338	$	6,474
Consumable and other products		6,262		2,840		828		9,930		8,915		4,483		790		14,188
Total	$	9,226		5,955		2,512	$	17,693	$	12,407	$	6,127	$	2,128	$	20,662
Service and other revenues
Service-type warranties	$	1,454	$	703	$	125	$	2,282	$	1,112	$	556	$	66	$	1,734
Research services		5,246		305		44		5,595		2,998		604		50		3,652
Other services		315		142		36		493		465		47		—		512
Total	$	7,015	$	1,150	$	205	$	8,370	$	4,575	$	1,207	$	116	$	5,898
Collaboration and license revenue
Collaboration and license revenue	$	136	$	165	$	—	$	301	$	73	$	47	$	—	$	120

	Nine Months Ended September 30, 2022								Nine Months Ended September 30, 2021
	North America		EMEA		Asia Pacific		Total		North America		EMEA		Asia Pacific		Total
Product revenues
Instruments	$	7,602	$	7,288	$	4,699	$	19,589	$	9,370	$	6,107	$	3,796	$	19,273
Consumable and other products		19,814		10,854		2,877		33,545		24,638		11,227		2,448		38,313
Total	$	27,416	$	18,142	$	7,576	$	53,134	$	34,008	$	17,334	$	6,244	$	57,586
Service and other revenues
Service-type warranties	$	4,057	$	2,050	$	341	$	6,448	$	3,181	$	1,452	$	179	$	4,812
Research services		16,853		752		65		17,670		9,285		2,095		89		11,469
Other services		916		590		104		1,610		1,271		403		—		1,674
Total	$	21,826	$	3,392	$	510	$	25,728	$	13,737	$	3,950	$	268	$	17,955
Collaboration and license revenue
Collaboration and license revenue	$	179	$	248	$	52	$	479	$	301	$	185	$	—	$	486

Schedule of changes in deferred revenue from contracts with customers

Changes in deferred revenue from contracts with customers were as follows (in thousands):

	2022		2021
Balance at December 31	$	7,460	$	5,998
Deferral of revenue		9,559		5,486
Recognition of deferred revenue		(6,452)		(4,812)
Balance at September 30	$	10,567	$	6,672

Schedule of costs to obtain a contract

	2022		2021
Balance at December 31	$	440	$	248
Deferral of costs to obtain a contract		1,182		558
Recognition of costs to obtain a contract		(914)		(435)
Balance at September 30	$	708	$	371

Schedule of summary of the activity under WP2

The following table summarizes the cumulative activity under the RADx Grant (in thousands):

	September 30, 2022		December 31, 2021
Grant revenue from research and development activities	$	9,576	$	9,576
Proceeds used for assets		8,624		8,104
Deferred proceeds for assets		—		—
Deferred grant revenue		—		—
Total recognized	$	18,200	$	17,680
Recognized	$	18,200	$	17,680
Amount accrued		—		—
Total cash received	$	18,200	$	17,680
Proceeds received	$	18,200	$	17,680
Proceeds reasonably assured		—		520
Total RADx Grant amount	$	18,200	$	18,200